Enveric Biosciences Inc.

2.24+0.0300+1.36%Vol 542.49K1Y Perf -67.86%
Jun 16th, 2021 16:00 DELAYED
BID2.22 ASK2.25
Open2.28 Previous Close2.21
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     62.31
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap47.91M 
Earnings Rating
Price Range Ratio 52W %
2.96 
Earnings Date
13th Aug 2021

Today's Price Range

2.182.30

52W Range

1.8515.04

5 Year PE Ratio Range

-14.50-0.6000

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-5.88%
1 Month
2.75%
3 Months
-38.96%
6 Months
-68.72%
1 Year
-67.86%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ENVB2.240.03001.36
AAPL130.46-1.3300-1.01
GOOG2 511.35-16.0700-0.64
MSFT259.43-1.4700-0.56
XOM60.40-1.5900-2.56
WFC41.75-1.0400-2.43
JNJ161.98-3.2400-1.96
FB329.66-6.8500-2.04
GE12.78-0.2200-1.69
JPM147.92-3.8400-2.53
Financial StrengthValueIndustryS&P 500US Markets
36.10
37.40
0.06
0.58
-28.20
Leverage Ratio 1.80
ProfitabilityValueIndustryS&P 500US Markets
238.70
84.00
84.00
-18.50
87.87
RevenueValueIndustryS&P 500US Markets
-9 602 530.00
-0.45
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021--0.20-
Q03 2020--0.20-
Q01 2020--0.60-
Q03 2019-0.00-
Q02 2019--0.03-
Q01 2019--0.04-
Q04 2018--0.30-
Q03 2018-0.05-0.08-60.00
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date13th Aug 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume542.49K
Shares Outstanding21.39M
Trades Count1.49K
Dollar Volume4.66M
Avg. Volume4.64M
Avg. Weekly Volume623.83K
Avg. Monthly Volume3.15M
Avg. Quarterly Volume1.71M

Enveric Biosciences Inc. (NASDAQ: ENVB) stock closed at 2.15 per share at the end of the most recent trading day (a 1.36% change compared to the prior day closing price) with a volume of 490.72K shares and market capitalization of 47.91M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3 people. Enveric Biosciences Inc. CEO is David I. Johnson.

The one-year performance of Enveric Biosciences Inc. stock is -67.86%, while year-to-date (YTD) performance is -47.42%. ENVB stock has a five-year performance of %. Its 52-week range is between 1.85 and 15.04, which gives ENVB stock a 52-week price range ratio of 2.96%

Enveric Biosciences Inc. currently has a PE ratio of 7.20, a price-to-book (PB) ratio of 2.68, a price-to-sale (PS) ratio of -5.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -30.09%, a ROC of -54.35% and a ROE of -55.07%. The company’s profit margin is 87.87%, its EBITDA margin is 84.00%, and its revenue ttm is $-9 602 530.00 , which makes it $-0.45 revenue per share.

Of the last four earnings reports from Enveric Biosciences Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Enveric Biosciences Inc.’s next earnings report date is 13th Aug 2021.

The consensus rating of Wall Street analysts for Enveric Biosciences Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Enveric Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enveric Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enveric Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 33.05, ATR14 : 0.20, CCI20 : -84.27, Chaikin Money Flow : -0.20, MACD : -0.02, Money Flow Index : 63.91, ROC : 0.45, RSI : 44.77, STOCH (14,3) : 11.29, STOCH RSI : 0.12, UO : 38.06, Williams %R : -88.71), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enveric Biosciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Enveric Biosciences Inc.

Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).

CEO: David I. Johnson

Telephone: +1 239 302-1707

Address: 4851 Tamiami Trail N, Naples 34103, FL, US

Number of employees: 3

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

50%50%

Bearish Bullish

67%33%

News

Stocktwits